From L-R: COO David Shoultz, CEO Daniel-Adriano Silva and CSO Alfredo Quijano Rubio (Monod Bio)

David Bak­er lab spin­out scores seed fund­ing to build a biosen­sor from en­gi­neered pro­tein

Af­ter em­bark­ing on the jour­ney of co-found­ing a biotech, Daniel-Adri­ano Sil­va was in search of his next mis­sion. He vis­it­ed David Bak­er’s lab­o­ra­to­ry at the Uni­ver­si­ty of Wash­ing­ton’s In­sti­tute for Pro­tein De­sign, where he had done his post-doc­tor­ate re­search. There, he re­con­nect­ed with Al­fre­do Qui­jano Ru­bio, who had just fin­ished his PhD and built a nov­el biosen­sor tech­nol­o­gy. The tech­nol­o­gy caught Sil­va’s at­ten­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA